Literature DB >> 7961573

An overview of the mechanism of action of clozapine.

H Y Meltzer1.   

Abstract

Clozapine has multiple clinical advantages that differentiate it from typical neuroleptics but that it may share with other novel antipsychotic drugs such as risperidone and olanzapine. There may be more than one pharmacologic feature that contributes to its advantages in improving psychopathology, cognition, affect, tardive dyskinesia, etc. Clozapine has < 10 nM affinity for the serotonin (5-HT)2A, 5-HT2C, 5-HT6, 5-HT7, D4, m1, and alpha 1-adrenergic receptor but weak affinity for the D2 receptor. Current evidence suggests the 5-HT2A and D4 receptor antagonist properties of clozapine, together with its weak D2 blocking properties, contribute the most to its advantages and should be sought in drug development programs. However, the other effects of clozapine may also be contributory. Clozapine is effective in a variety of conditions and at a range of plasma levels. The effects that are important in various indications may differ.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961573

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  51 in total

Review 1.  The challenges of psychopharmacogenetics.

Authors:  M Catalano
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

2.  The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.

Authors:  Eunice Y Yuen; Xiangning Li; Jing Wei; Masakuni Horiguchi; Herbert Y Meltzer; Zhen Yan
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

Review 3.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 4.  The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.

Authors:  Holly Moore
Journal:  Schizophr Bull       Date:  2010-09-24       Impact factor: 9.306

Review 5.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

6.  Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation.

Authors:  R Hammock; W R Levine; S R Schroeder
Journal:  J Autism Dev Disord       Date:  2001-02

7.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

Authors:  István Gyertyán; Katalin Sághy; Judit Laszy; Ottilia Elekes; Rita Kedves; Larisza I Gémesi; Gabriella Pásztor; Mária Zájer-Balázs; Margit Kapás; Eva Agai Csongor; György Domány; Béla Kiss; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

8.  Hyperdopaminergic tone erodes prefrontal long-term potential via a D2 receptor-operated protein phosphatase gate.

Authors:  Tai-Xiang Xu; Tatyana D Sotnikova; Chengyu Liang; Jingping Zhang; Jae U Jung; Roger D Spealman; Raul R Gainetdinov; Wei-Dong Yao
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

9.  Anatomically Defined and Functionally Distinct Dorsal Raphe Serotonin Sub-systems.

Authors:  Jing Ren; Drew Friedmann; Jing Xiong; Cindy D Liu; Brielle R Ferguson; Tanya Weerakkody; Katherine E DeLoach; Chen Ran; Albert Pun; Yanwen Sun; Brandon Weissbourd; Rachael L Neve; John Huguenard; Mark A Horowitz; Liqun Luo
Journal:  Cell       Date:  2018-08-23       Impact factor: 41.582

10.  Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia.

Authors:  Takahiro Shinkai; Osamu Ohmori; Chima Matsumoto; Hiroko Hori; James L Kennedy; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.